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ABSTRACT
Background: Previously published research that examined the ef-
fects of high egg consumption in people with type 2 diabetes (T2D)
produced conflicting results leading to recommendations to limit
egg intake. However, people with T2D may benefit from egg con-
sumption because eggs are a nutritious and convenient way of im-
proving protein and micronutrient contents of the diet, which have
importance for satiety and weight management.
Objective: In this randomized controlled study, we aimed to de-
termine whether a high-egg diet (2 eggs/d for 6 d/wk) compared
with a low-egg diet (,2 eggs/wk) affected circulating lipid profiles,
in particular high-density lipoprotein (HDL) cholesterol, in over-
weight or obese people with prediabetes or T2D.
Design: A total of 140 participants were randomly assigned to one
of the 2 diets as part of a 3-mo weight maintenance study. Partic-
ipants attended the clinic monthly and were instructed on the spe-
cific types of foods and quantities to be consumed.
Results: There was no significant difference in the change in HDL
cholesterol from screening to 3 mo between groups; the mean difference
(95% CI) between high- and low-egg groups was +0.02 mmol/L (20.03,
0.08 mmol/L; P = 0.38). No between-group differences were shown for
total cholesterol, low-density lipoprotein cholesterol, triglycerides, or gly-
cemic control. Both groups were matched for protein intake, but the
high-egg group reported less hunger and greater satiety postbreak-
fast. Polyunsaturated fatty acid (PUFA) and monounsaturated fatty acid
(MUFA) intakes significantly increased from baseline in both groups.
Conclusions: High egg consumption did not have an adverse effect
on the lipid profile of people with T2D in the context of increased
MUFA and PUFA consumption. This study suggests that a high-egg
diet can be included safely as part of the dietary management of
T2D, and it may provide greater satiety. This trial was registered at
the Australia New Zealand Clinical Trials Registry (http://www.
anzctr.org.au/) as ACTRN12612001266853. Am J Clin Nutr
2015;101:705–13.
Keywords: cardiovascular disease, cholesterol, lipids, obesity,
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INTRODUCTION
Type 2 diabetes (T2D)5 is one of the most-common chronic
diseases worldwide (1). Therefore, interventions to manage T2D
and its complications are a priority. Currently, guidelines differ
between countries regarding egg consumption and total dietary
cholesterol intake (2–4). The Australian National Heart Foun-
dation recommends a maximum of 6 eggs/wk for healthy people
and those with T2D (2), whereas US guidelines for people with
T2D recommend that dietary cholesterol be limited to,300 mg/
d (one egg containsw200 mg cholesterol) and ,4 eggs/wk (3).
However, in the United Kingdom, there is no suggested limit on
the number of eggs consumed, and instead, emphasis is placed
on a dietary reduction of SFAs (4).
Eggs contain a number of nutrients (5, 6) that may reduce risk
of T2D and cardiovascular disease (CVD), including folate (7)
and arginine (8, 9). Eggs were also shown to increase circulating
concentrations of HDL cholesterol (10, 11), which is associated
with reduced CVD risk (12). Although eggs are rich in choles-
terol, the total amount of fat is not high (5.2 g) and is pre-
dominantly unsaturated (51% MUFAs; 16% PUFAs) (5). In
addition, their high protein content might improve satiety (13)
thereby assisting with weight management.
Despite the positive nutritional value of eggs, there is a neg-
ative perception toward egg consumption for people with T2D. A
number of epidemiologic studies indicated that high egg con-
sumption, although not associated with adverse CVD outcomes
in the general population, may be associated with worse CVD
outcomes in people with T2D (14–16). However, the findings in
such studies were affected by many confounding factors. For
example, at the time that these epidemiologic studies were being
conducted, a public health campaign advised people to limit
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their cholesterol intake, including their consumption of eggs.
Individuals who consumed .6 eggs/wk at that time may have
been less likely to follow healthy dietary and lifestyle advice in
general.
Furthermore, there is a lack of good-quality prospective data
on the effects of high egg consumption in people with T2D. To
our knowledge, there has only been one short-duration ran-
domized controlled trial in people with T2D (10). In this study,
people with T2D who consumed a high-cholesterol (2 eggs/d),
reduced-energy diet lost the same amount of weight and had
similar improvements in circulating lipid concentrations, blood
pressure, and glycemic control as did thosewho consumed an iso-
energetic low-cholesterol diet.
To address the limitations of previous research, this prospective
randomized controlled study had a 3-mo active-intervention period
of weight maintenance to determine the potential health effects of
a high-egg diet in people with prediabetes and T2D. We hy-
pothesized that there would be a significant increase in HDL
cholesterol with high egg intake and that subjects in the high-egg
group would report greater satiety.
METHODS
Study design and participants
This prospective, randomized controlled, parallel-arm study
was conducted in accordance with International Conference on
Harmonization–Good Clinical Practice guidelines. A total of
140 participants, aged $18 y, who were diagnosed with pre-
diabetes or T2D and had BMI (in kg/m2) $25 were recruited
from the Boden Institute database, the Sydney Local Health
District intranet, the University of Sydney website, and adver-
tising in local newspapers. Prediabetes and T2D inclusion cri-
teria were based on American Diabetes Association Guidelines
(17). Participants diagnosed with T2D and taking antidiabetic
medications were included.
Participants were excluded if they had T2D and glycated he-
moglobin (Hb A1c) .9.5%; unstable angina or recent onset of
CVD (#1 mo of screening); a history of significant liver, kidney,
or gastrointestinal disease; untreated thyroid disease; a history or
presence of malignancy; a history of alcohol abuse or illicit
drug use; previous gastric surgery or gastric banding; used
weight loss medications or other drugs that affect body weight
#3 mo of screening; commenced a new medication or a change
in dose regimen of prescription medication #3 mo of screen-
ing; were pregnant, breastfeeding, or planning a pregnancy during
the study; followed vegetarian eating practices; had an egg allergy;
or changed smoking habits or ceased smoking #6 mo before
screening.
Participants who were taking hypoglycemic or hypolipidemic
agents were not excluded from the study. When possible, par-
ticipants were required to keep their diabetic and cholesterol
medications and dosages constant throughout the study. This was
done in conjunction with their primary care providers.
All experimental procedures were approved by the University
of Sydney Human Ethics Review Committee, and all participants
provided written informed consent. All clinic visits took place at
the Boden Institute, the University of Sydney. This trial was
registered at the Australia New Zealand Clinical Trials Registry
(http://www.anzctr.org.au/) as ACTRN12612001266853.
Dietary interventions
Participants were randomly assigned in a 1:1 ratio to either
a high- or low-egg diet. Participants met the study dietitian at the
baseline visit (#1 wk of the screening visit) and were advised
about their diet allocation and diet prescription for weight
maintenance. Participants who consumed the high-egg diet were
instructed to eat 2 eggs/d at breakfast for 6 d/wk (12 eggs/wk).
Subjects in the low-egg group were directed to consume
,2 eggs/wk and match the protein intake of the high-egg group at
breakfast with 10 g lean animal protein (meat, chicken, or fish)
or other protein-rich alternatives such as legumes and reduced
fat dairy products. Participants were given a booklet as a guide
to the specific types of foods and quantities to be consumed with
particular emphasis on replacing foods containing saturated fats
with foods containing MUFAs and PUFAs to improve diet
quality and maintain energy intake over the 3 mo (Supple-
mental Material 1). The diets were energy and macronutrient
matched. Participants were instructed not to change their ac-
tivity level. To aid with compliance, participants who consumed
the high-egg diet were given the prescribed quota of eggs, and
participants who consumed the low-egg diet received a grocery
voucher of equivalent value (5 Australian dollars/wk; 20 Aus-
tralian dollars/mo).
Primary and secondary outcomes
All major assessments were conducted at screening (anthro-
pometric measures, vital signs, and pathology), baseline (nutri-
tional analysis and questionnaires), and 3 mo (all outcomes).
Body weight, waist circumference, the recording of side effects,
any medication changes, and a dietetic review were conducted at
monthly visits. Participants attended the clinic at week 2 of the
study to ensure they were not losing weight after the imple-
mentation of the initial dietary changes. The primary outcome for
the study was the change in HDL cholesterol at 3 mo. All other
assessments were secondary outcomes.
Pathology
Blood samples were collected for fasting blood glucose, Hb
A1c, total cholesterol, HDL cholesterol, LDL cholesterol, high-
sensitivity C-reactive protein, and apolipoprotein B. Blood was
also collected for a full blood count, thyroid function, and liver
and renal function to assess eligibility criteria at the screening
visit.
Change in anthropometric measures and vital signs
Height was measured by using a wall-mounted stadiometer
(accurate to 0.5 cm), body weight was measured by using
a calibrated scale (correct to the nearest 0.1 kg), waist circum-
ference was measured at the midpoint between the highest point
of the iliac crest and lowest part of the costal margin in the
midaxillary line (to the nearest 0.5 cm), mean systolic and di-
astolic blood pressures were measured twice in the same arm each
time (if a difference .10 mm Hg was shown in either reading,
a third reading was taken; each measure was taken by using the
same digital sphygmomanometer), heart rate was measured by
using the radial pulse, and total body fat and fat-free mass were
measured by using a bioelectrical impedance analysis (Tanita
BC Analyzer BC-418; Tanita).
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Nutritional analysis
Aweighed 5-d (self-reported) food diary (4 working days and
one weekend day) was collected by the dietitian at the baseline
and 3-mo visits. Food diaries were analyzed with Food Works 7
Professional (version 7) software (2013; Xyris Software) on the
basis of Australian Food Composition tables and food manu-
facturers’ data. Dietary compliance was defined and measured
primarily by the quantity of eggs reported in the 5-d food di-
aries. Subjects who consumed $12 eggs/wk were compliant in
the high-egg group, and subjects who consumed,2 eggs/d were
compliant in the low-egg group. We also assessed intakes of
saturated fat, MUFAs, and PUFAs as a measure of compliance
because this was in line with the dietary prescription that was
provided (Supplemental Material 1).
Questionnaires
The following questionnaires were completed by participants
at baseline and 3 mo: 1) the Three-Factor Eating Questionnaire-
R21 (18), 2) the International Physical Activity Questionnaire–
short version (19), 3) the Impact of Weight on Quality of Life
Questionnaire-Lite Version (20), 4) The Food Acceptability
Questionnaire (21, 22), and 5) a visual analog scale [an appetite
score for before and after breakfast (23)] whereby participants
were required to answer questions 30 min before and after
breakfast).
Statistical analysis
Sample size. A total of 140 participants were recruited into the
study. With the assumption of a detectable difference in HDL
cholesterol of 0.12 mmol/L between the 2 groups at 3 mo and an
SD of 0.24 mmol/L, 126 participants were required to achieve
80% power of detecting a treatment effect (2-sided significance
level of 5%). With allowance for a 10% dropout rate over the
3 mo, a sample size of 140 was needed to enable adequate power to
assess our primary outcome of a 10% difference in HDL cho-
lesterol between the 2 groups as shown in a previous study (11).
Random assignment. Treatment groups were stratified during
random assignment according to age, sex, cholesterol medication
treatment, and diabetes status (prediabetes or T2D). Once stratified,
participants were randomly allocated by using computer-generated
random numbers to either the high- or low-egg–diet group. This
allocation was performed by one of the investigators (GD) who
did not have any involvement with participant contact or clinic
visits. Furthermore, outcome assessors were blinded to the treat-
ment allocation during the data analysis.
Data analysis. The statistical analysis was performed with
SPSS 19.0 software (SPSS). All participants who were randomly
assigned and completed an initial assessment were included in the
final results by using an intention-to-treat analysis. Multiple
imputation with the use of linear regression was used to impute
missing values from screening/baseline to 3 mo and was based on
the assumption that data were missing at random. Five imputed
data sets were created for each variable. An ANCOVAwas used
to compare treatment groups. Analyses were adjusted for the
screening/baseline observation. An ANOVA with repeated
measures was used for within-group comparisons. A completer’s
analysis was also performed for the primary and secondary
outcomes, whereby only subjects who completed the outcome
measures and were dietary compliant to the high- or low-egg
diet were included as assessed by the number of eggs reported in
the food diary per week. A 2-sided P , 0.05 was considered
statistically significant. Values are presented as mean (6SDs).
Between-group differences are presented as means (95% CIs)
and represent the d change between screening/baseline and 3 mo
for the 2 groups. Differences in screening/baseline characteris-
tics were analyzed by using independent sample t tests.
RESULTS
Trial disposition
A flowchart that detailed the participant disposition is provided
in Figure 1. The study was conducted between January and
September 2013. There was a dropout rate of 9% [8.6% = 12
participants (6 subjects from each group)] at the end of the 3-mo
intervention. Of subjects who completed the 3 mo, 7 participants
were considered to be noncompliant to their allocated diet (i.e.,
did not follow the high- or low-egg–diet prescription) (Figure 1).
Baseline characteristics
Baseline characteristics of participants are detailed in Table 1.
Demographic and clinical characteristics were well matched
across the 2 groups, although there were significant differences
at baseline in total cholesterol (0.30; P = 0.04) and HDL cho-
lesterol (0.10; P = 0.03) with higher values shown in the high-
egg group. There was no significant difference in mean years
diagnosed with T2D, which were 7.3 and 5.5 y for high and low-
egg–diet groups, respectively. Baseline dietary intake was the
same in both groups (Table 2).
Medication changes
Changes in hypolipidemic agents during the 3-mo study oc-
curred in 3 participants in the low-egg group (one subject ceased
rosuvastatin, and 2 subjects had an increase in statin dose). One
participant in the high-egg group commenced a psoriasis med-
ication (acitretin) that is an agent with a known adverse effect on
lipid profile. A combined antihypertensive and hypolipidemic
agent (amlodipine/atorvastatin) was commenced by one partic-
ipant in the high-egg group. Two participants in the high-egg
group had changes in hypoglycemic medication during the 3-mo
study (one subject commenced exenatide, and one subject had
a decreased dosage of 30% soluble insulin aspart:70% protamine-
crystallized insulin aspart), and 5 participants in the low-egg
group recorded changes [one subject commenced gliclazide, one
subject increased the dosage of insulin, isophane (rys), one
subject changed medication from sitagliptin/metformin to
vildagliptin/metformin, one subject commenced metformin, and
one subject commenced sitagliptin]. Five participants in the high-
egg group had changes in antihypertensive medication during the
3-mo study (one subject increased the dosage of candesartan, one
subject commenced labetalol, one subject increased the dosage of
perindopril/amlodipine, one subject reduced the dosage of per-
indopril, and one subject reduced the dosage of perindopril/
amlodipine), and 3 participants in the low-egg group recorded
changes (one subject commenced candesartan, one subject in-
creased the dosage of perindopril/amlodipine, and one subject
reduced the dosage of ramipril and commenced amlodipine/
telmisartan). These medication changes did not influence the
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primary or secondary outcome results because the findings were
the same regardless of whether or not these participants’ data
were included in the intention-to-treat statistical analyses (see
primary and secondary descriptive results).
Primary outcome
There was no significant difference in HDL cholesterol from
screening to 3 mo between the 2 groups (mean difference for
high-egg group compared with low-egg group: +0.02 mmol/L;
95% CI: 20.03, 0.08 mmol/L; P = 0.38) (Table 3). This result
was the same for participants who completed the 3-mo study and
were dietary compliant (n = 121; high-egg group: n = 60; low-
egg group: n = 61; mean difference for high-egg group com-
pared with low-egg group:+0.04 mmol/L; 95% CI: 20.01, 0.09
mmol/L; P = 0.15). Again, when we analyzed only subjects with
T2D, there was no statistical difference between groups (n =
103; mean difference for high-egg group compared with low-
egg group: +0.02 mmol/L; 95% CI: 20.05, 0.08 mmol/L; P =
0.65), and this result held when participants who maintained
stable lipid-medication usage during the study (n = 135) were
analyzed (mean difference for high-egg group compared with
low-egg group: +0.03 mmol/L; 95% CI: 20.02, 0.08 mmol/L;
P = 0.26).
Secondary outcomes
Change in total cholesterol, LDL cholesterol, and triglycerides
There were no significant differences in total cholesterol, LDL
cholesterol, triglycerides, or apolipoprotein B from screening to 3
mo between the 2 groups (Table 3). These results were consistent
when we analyzed only those participants who maintained stable
lipid medication during the study (i.e., no change in medications
from baseline), completers only, or only subjects who were
compliant with their respective diet (results not shown).
Change in glycemic control
There were no significant differences in fasting glucose or Hb
A1c (%) from screening to 3 mo between the 2 groups (Table 3).
FIGURE 1 Flow diagram of participants through the study. Hb A1c, glycated hemoglobin.
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This result was also consistent when we analyzed participants
who maintained stable antidiabetic medication throughout the
study, completers only, or only subjects who were compliant to
their respective diet (results not shown).
Change in anthropometric measures and vital signs
Participants successfully maintained their body weight #1 kg
of their initial weight, and there were no significant differences
in weight change over the 3-mo period between groups. Simi-
larly, no differences in waist circumference, total body fat, fat-
free mass, blood pressure, or heart rate between groups were
identified (Table 3).
Dietary changes
At 3 mo, when all participants (n = 140) were included, the
high-egg group reported consuming a mean (6SD) of 11.8 6
3.6 eggs/wk; whereas the low-egg group reported consuming
1.0 6 1.8 eggs/wk.
There was no difference between groups for protein intake
from baseline to 3 mo. A small but significant difference was
evident between groups from baseline to 3 mo for carbohydrate,
total fat, and fiber intake (Table 4). Saturated fat intake de-
creased significantly in both groups from 14.0% and 13.7% to
13.3% and 11.4% of total fat intake at 3 mo for high- and low-
egg groups, respectively. PUFA and MUFA intakes significantly
TABLE 1
Screening characteristics of study participants (n = 140)
Characteristics High-egg group (n = 72) Low-egg group (n = 68)
Sex (F), n (%) 39 (54) 38 (56)
Prediabetic, n (%) 21 (29) 16 (23.5)
Type 2 diabetic, n (%) 51 (71) 52 (76.5)
Years diagnosed with type 2 diabetes 7.3 6 7.61 5.5 6 4.8
Age, y 59.5 6 9.7 60.1 6 11.1
.45 y, n (%) 66 (92) 60 (88)
BMI, kg/m2 35.4 6 6.4 33.7 6 5.9
Taking cholesterol medication, n (%) 40 (56) 35 (52)
HDL cholesterol, mmol/L 1.3 6 0.3 1.2 6 0.22
LDL cholesterol, mmol/L 2.9 6 0.9 2.6 6 1.03
Total cholesterol, mmol/L 5.0 6 1.1 4.7 6 1.14
Triglycerides, mmol/L 1.7 6 0.7 1.8 6 0.8
Fasting blood glucose, mmol/L 6.7 6 1.7 6.9 6 1.7
Hb A1c,
5 % 6.6 6 1.0 6.6 6 0.9
Hb A1c, mmol/mol 48.0 6 11.4 48.9 6 9.9
C-reactive protein, mg/L 5.1 6 5.4 4.9 6 8.5
Apolipoprotein B, g/L 1.1 6 0.3 1.0 6 0.3
Weight, kg 98.0 6 20.4 93.3 6 17.8
Waist circumference, cm 111.4 6 13.7 109.6 6 13.8
Total body fat, % 29.4 6 11.0 29.0 6 10.5
Fat-free mass, kg 69.7 6 19.7 66.5 6 17.7
Systolic blood pressure, mm Hg 136.0 6 18.0 136.6 6 14.6
Diastolic blood pressure, mm Hg 82.2 6 10.2 82.4 6 7.6
Radial pulse rate, beats/min 70.3 6 9.2 71.7 6 11.3
1Mean 6 SD (all such values).
2– 4P values of baseline differences between groups (t tests were used for the comparison of means between groups):
2P = 0.03, 3P = 0.05, 4P = 0.04.
5Hb A1c, glycated hemoglobin.
TABLE 2
Baseline dietary intake of study participants (n = 138)1
Characteristics High-egg group (n = 70) Low-egg group (n = 68)
Energy, kJ 7795 6 2259 7374 6 1837
Protein, percentage of energy 20.4 6 3.9 20.7 6 4.9
Carbohydrates, percentage of energy 40.3 6 7.3 41.6 6 7.7
Total fat, percentage of energy 33.4 6 5.9 32.2 6 6.1
Alcohol, percentage of energy 2.6 6 4.2 2.4 6 3.8
Saturated fat, percentage of total fat 42.0 6 5.3 42.7 6 6.2
Polyunsaturated fat, percentage of total fat 17.3 6 3.7 17.2 6 4.6
Monounsaturated fat, percentage of total fat 40.6 6 3.9 40.1 6 4.1
Dietary fat, g 22.5 6 8.0 20.3 6 6.3
Cholesterol, mg 318.2 6 140.6 298.8 6 141.0
1All values are means 6 SDs. Two participants (high-egg group) did not complete a baseline food diary. Dietary
intakes are written as a percentage of total energy intake unless otherwise indicated. t tests were used for the comparison of
means between groups. No significant differences were shown for any of the characteristics between groups.
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increased from baseline in both groups (Table 4). These findings
were in keeping with the dietary prescription for both groups to
replace “bad” fats with “good” fats. However, there were no
significant differences in the change in saturated fat, poly-
unsaturated fat, and monounsaturated fat intakes between groups
with the dietary intervention. As expected, there was a signifi-
cant difference between groups from baseline to 3 mo for dietary
cholesterol (Table 4).
Food acceptability
Both groups reported an increase in overall satisfaction of the
diet they were allocated compared with baseline dietary habits
with results favoring the high-egg group (Table 5). Analyses
between groups indicated significant differences that favored the
high-egg group for the enjoyment of the foods they were eating
and being less bored with food choices. A trend toward being
more satisfied with the high-egg diet compared with low-egg
diet was also evident (Table 5).
Appetite
There were no differences in the before-breakfast appetite
ratings between the 2 groups at 3 mo. However, the high-egg
group reported significantly less hunger after breakfast (question
1: “How hungry are you?”) and significantly greater satiety
TABLE 3
Change from screening for blood pathology results, anthropometric variables, and vital signs at 3 mo (n = 140)1
Variables High-egg group (n = 72)2 Low-egg group (n = 68)2
Between-group comparison
(high egg relative to low egg)3
HDL cholesterol (primary efficacy), mmol/L 0.034 6 0.158 (0.07) 0.029 6 0.170 (0.17) 0.024 (20.030, 0.077) [0.38]
LDL cholesterol, mmol/L 20.06 6 0.64 (0.44) 0.05 6 0.59 (0.54) 20.02 (20.22, 0.17) [0.81]
Total cholesterol, mmol/L 20.04 6 0.75 (0.62) 0.02 6 0.69 (0.85) 0.03 (20.20, 0.26) [0.81]
Triglycerides, mmol/L 20.07 6 0.51 (0.22) 20.11 6 0.58 (0.12) 0.00 (20.16, 0.16) [0.99]
Fasting blood glucose, mmol/L 20.35 6 3.61 (0.42) 20.06 6 1.31 (0.69) 20.39 (21.29, 0.51) [0.39]
Hb A1c, % 20.07 6 0.43 (0.20) 20.11 6 0.46 (0.05) 0.04 (20.11, 0.19) [0.61]
Hb A1c, mmol/mol 20.58 6 5.01 (0.33) 21.25 6 5.00 (0.04) 0.60 (21.05, 2.25) [0.48]
hsCRP, mg/L 20.59 6 4.44 (0.26) 20.76 6 9.75 (0.52) 0.32 (21.70, 2.34) [0.75]
Apolipoprotein B, g/L 20.04 6 0.37 (0.32) 20.05 6 0.17 (0.02) 0.02 (20.07, 0.12) [0.64]
Weight, kg 20.48 6 2.13 (0.06) 20.91 6 1.96 (,0.0001) 0.43 (20.25, 1.12) [0.21]
Waist circumference, cm 0.35 6 2.60 (0.26) 20.16 6 3.96 (0.74) 0.51 (20.60, 1.62) [0.37]
Total body fat, % 1.33 6 3.95 (,0.01) 1.03 6 4.14 (0.04) 0.30 (21.05, 1.65) [0.66]
Fat-free mass, kg 21.94 6 5.12 (,0.01) 21.86 6 4.56 (0.001) 20.08 (21.70, 1.54) [0.92]
Systolic blood pressure, mm Hg 21.54 6 17.61 (0.46) 25.42 6 13.63 (,0.01) 3.88 (21.40, 9.16) [0.15]
Diastolic blood pressure, mm Hg 23.05 6 6.60 (,0.0001) 23.82 6 6.83 (,0.0001) 0.77 (21.47, 3.01) [0.50]
Radial pulse rate, beats/min 21.06 6 6.89 (0.90) 1.57 6 6.82 (0.06) 21.68 (23.97, 0.61) [0.15]
1An ANCOVA was used to compare treatment groups. Analyses were adjusted for the screening observation. An ANOVA with repeated measures was
used for within-group comparisons. Hb A1c, glycated hemoglobin, hsCRP, high-sensitivity C-reactive protein.
2All values are mean differences 6 SDs; P values in parentheses. P values represent within-group differences from screening to 3 mo.
3All values are mean differences; 95% CIs in parentheses; P values in brackets. P values represent between-group differences from screening to 3 mo
after adjustment for the screening value.
TABLE 4
Change from baseline in mean dietary intake at 3 mo (n = 135)1
Variables High-egg group (n = 67)2 Low-egg group (n = 68)2
Between-group comparison
(high egg relative to low egg)3
Energy, kJ4 2346.4 6 3006.2 (0.35) 211.2 6 2028.0 (0.96) 0.5 (2672.9, 673.8) [0.99]
Protein, percentage of energy 2.7 6 8.9 (0.02) 0.9 6 5.3 (0.17) 1.7 (20.5, 3.9) [0.14]
Carbohydrates, percentage of energy 23.9 6 7.2 (,0.0001) 21.1 6 8.3 (0.29) 23.5 (25.8, 21.2) [,0.01]
Total fat, percentage of energy 1.4 6 7.6 (0.15) 20.5 6 7.4 (0.57) 2.5 (0.2, 4.8) [0.04]
Alcohol, percentage of energy 20.3 6 2.7 (0.42) 0.0 6 2.7 (0.97) 20.3 (21.2, 0.6) [0.57]
Saturated fat, percentage of total fat 23.7 6 11.7 (0.01) 26.5 6 8.2 (,0.0001) 2.3 (20.8, 5.4) [0.14]
Polyunsaturated fat, percentage of total fat 1.8 6 6.6 (0.03) 3.6 6 5.5 (,0.0001) 21.7 (23.7, 0.2) [0.08]
Monounsaturated fat, percentage of total fat 2.5 6 5.3 (,0.0001) 2.6 6 5.7 (,0.0001) 0.3 (21.2, 1.7) [0.71]
Dietary fiber, g 20.2 6 8.0 (0.85) 3.6 6 7.2 (,0.0001) 22.6 (24.9, 20.4) [0.02]
Cholesterol, mg 281.5 6 267.6 (,0.0001) 236.2 6 196.3 (0.13) 337.2 (271.7, 402.7) [,0.0001]
1Five participants did not return more than one food diary. Each dietary variable is written as a percentage of total energy intake unless otherwise
indicated. An ANCOVA was used to compare treatment groups. Analyses were adjusted for baseline observation. An ANOVA with repeated measures was
used for within-group comparisons.
2All values are mean differences 6 SDs; P values in parentheses. P values represent within-group differences from baseline to 3 mo.
3All values are mean differences; 95% CIs in parentheses; P values in brackets. P values represent between-group differences from baseline to 3 mo after
adjustment for the baseline value.
41 kJ = 0.239 kcal.
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(question 4: “How much food do you think you can eat?”) than
the low-egg group (Table 6).
Eating behavior, physical activity, and quality of life
There were no significant differences between groups in the 3
domains of eating behavior (as determined by using the Three-
Factor Eating Questionnaire-R21) over the 3 mo. Similarly, there
was no difference between groups in the total time spent par-
taking in physical activity per week (median difference for high-
egg group compared with low-egg group: 0; IQR:2999 to 1449;
P = 0.92). With respect to quality of life, there were no differ-
ences between groups over the 3-mo period (mean difference for
the high-egg group compared with the low-egg group: 22.2;
95% CI: 25.3, 0.9; P = 0.17).
DISCUSSION
With the rising prevalence of T2D, there is an urgent need to
provide clear messages for both its treatment and prevention. On
the basis of published research to date, it is unclear whether eggs
are a safe and suitable dietary protein source for people with T2D
who are at high risk of cardiovascular complications.
There is little or no association between egg intake and CVDs
in a range of healthy populations (24), and eggs may actually
improve risk factors associated with CVD in this group (25).
Therefore, the current prospective randomized controlled trial
was designed to address the confounding factors of the published
epidemiologic evidence to date, which suggests that a high-egg
diet may be associated with detrimental outcomes in people with
T2D (14–16). At the end of this 3-mo study, there were no
significant differences in circulating concentrations of HDL
cholesterol, LDL cholesterol, total cholesterol, or triglycerides
between subjects in the 2 groups (the high- or low-egg diet).
Although both groups significantly reduced their saturated fat
intakes, there was a within-group trend toward an improvement
in HDL cholesterol only in the high-egg group. This finding was
in keeping with several studies in nondiabetic populations that
showed increases in HDL cholesterol and apolipoprotein A-I
concentrations with increased egg intake, with minimal effects
on LDL cholesterol, particularly in obese insulin-resistant sub-
jects in whom dietary cholesterol absorption is reduced (10, 11,
26). A possible explanation for this finding is that the formation
of intestinal apolipoprotein A-I, which is the major protein
component of HDL cholesterol, was shown to be increased with
cholesterol and fat feeding in both insulin-sensitive and, albeit to
a lesser extent, insulin-resistant subjects (26). This is a possible
area of future research to confirm whether a high-egg diet in
individuals with T2D is beneficial in raising HDL cholesterol.
Interventions that were associated with increases in HDL cho-
lesterol, such as the use of fenofibrate, were shown to reduce
cardiovascular events in people with T2D (27). In the Fenofibrate
Intervention and Event Lowering in Diabetes study, in which
fenofibrate or placebo was given to participants with T2D (27),
a 0.05-mmol/L increase in HDL cholesterol was evident over
4 mo for subjects taking fenofibrate. This increase was sustained to
a lesser extent throughout the duration of the study, which perhaps
contributed to the positive finding in relation to cardiovascular
events.
Thus far, there has been only one prospective randomized
controlled trial that examined the effect of eggs in people with
T2D (10). Although there was an improvement in blood lipid
profiles, the result was possibly confounded by the trial being
TABLE 5
Average scores for each group at baseline and 3 mo for the FAQ1
High-egg diet (n = 70)2 Low-egg diet (n = 67)2
Between-group comparison
(high egg relative to low egg)3
Baseline D 3 mo Baseline D 3 mo D 3 mo
Question 1 5.5 6 1.0 0.0 6 1.0 5.4 6 0.9 20.2 6 1.1 0.3 (0.0, 0.6) [0.04]
Question 2 5.5 6 0.9 20.1 6 0.9 5.4 6 0.9 20.3 6 0.9 0.2 (20.0, 0.5) [0.07]
Question 3 5.2 6 1.1 20.2 6 1.1 5.0 6 1.0 20.1 6 1.2 0.1 (20.2, 0.4) [0.6]
Question 4 3.1 6 1.4 20.2 6 1.4 3.3 6 1.6 0.3 6 1.6 20.6 (21.0, 20.2) [#0.01]
Question 5 5.5 6 1.4 20.2 6 1.5 5.3 6 1.4 20.2 6 1.4 0.1 (20.3, 0.5) [0.6]
Question 6 5.8 6 1.2 20.2 6 1.3 6.0 6 1.1 20.4 6 1.3 0.1 (20.3, 0.4) [0.7]
Question 7 4.0 6 1.6 20.1 6 1.6 4.5 6 1.5 20.5 6 1.4 0.2 (20.2, 0.7) [0.3]
Question 8 4.3 6 1.6 0.0 6 1.8 4.5 6 1.5 20.2 6 1.5 0.2 (20.3, 0.6) [0.4]
Question 9 5.0 6 1.4 0.2 6 1.3 4.9 6 1.3 0.2 6 1.5 0.0 (20.3, 0.4) [0.9]
Question 10 4.6 6 1.4 0.6 6 1.4 4.8 6 1.3 0.1 6 1.3 0.3 (20.0, 0.7) [0.06]
1The FAQ was composed of the following 10 questions scored on a 7-point linear scale with 1 being dislike and 7
being total acceptance (the exception was for question 4 for which the reverse applied): Question 1: How well do you like
the food that you have been eating in the past 2 wk? Question 2: How well do you like the taste of these foods? Question 3:
How appealing or unappealing do you find the appearance of these foods? Question 4: How boring are these foods?
Question 5: How easy or difficult has it been for you to prepare these foods? Question 6: How easy or difficult has it been
for you to purchase these foods? Question 7: How easy or difficult has it been for you to maintain your current diet at
restaurants? Question 8: How much effort does it take for you to stay on this diet? Question 9: How satisfied or dissatisfied
do you feel after eating a meal on this diet? Question 10: Overall, how satisfied or dissatisfied are you with this diet?
Positive D values represent an increase from baseline; negative D values represent a decrease from baseline. An ANCOVA
was used to compare treatment groups. Analyses were adjusted for the baseline observation. An ANOVA with repeated
measures was used for within-group comparisons. P values represent between-group differences from baseline to 3 mo after
adjustment for the baseline value. FAQ, Food Acceptability Questionnaire.
2All values are means 6 SDs.
3All values are means; 95% CIs in parentheses; P values in brackets.
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a weight-loss intervention. Weight loss itself has effects on blood
lipid profiles that might outweigh any effects of eggs on such
variables. In the current study, participants were instructed to
maintain their weight by replacing energy-dense, nutrient-poor
foods that were high in saturated fats with energy-dense, nutrient-
rich alternatives that were high in monounsaturated and poly-
unsaturated fats. Both groups successfully maintained their
weight to #1 kg of their initial body weight. Despite a within-
group significant weight loss or reduction in body fat percentage
in both groups, the amount of weight loss was small and not
clinically meaningful such that our observations were unlikely
to be confounded by concurrent weight changes.
Despite the high protein content of eggs, the protein intake of
both groups was matched for the period of the 3-mo study. A
small but significant difference in carbohydrate and total fat
intake was noted between groups at 3 mo, which may have been
due to the higher fat and lower carbohydrate content of eggs
compared with other protein-rich sources prescribed at breakfast
for the low-egg group (e.g., skim/low fat dairy, baked beans, and
lean meat). Intakes of saturated fat decreased significantly for
both groups and intakes of polyunsaturated and monounsaturated
fats increased significantly for both groups. However, the
American Diabetes Association guidelines suggest saturated fat
should be ,10% of the total energy in the diet for the general
population and people with T2D (3), and in our study, partici-
pants’ intakes were still above this target. Participants in the
high-egg group also consumed approximately double the current
American Diabetes Association guidelines for cholesterol intake
(3). Despite being above the American Diabetes Association
guidelines for saturated fat and cholesterol intakes, these results
show that a high-egg diet can be incorporated into the dietary
management of people with T2D in conjunction with an increase
in monounsaturated and polyunsaturated fats without adversely
affecting blood lipid profiles. However, it is not known how high
egg consumption would influence the metabolic profile of peo-
ple consuming a low-MUFA and -PUFA diet, compared with
that of control subjects consuming a low-MUFA and -PUFA diet
because this was not a part of our study design.
Although both diets werewell adopted over the 3-mo study, the
high-egg diet showed a significantly greater food-acceptability
score compared with that with the low-egg diet. This finding
suggests a high-egg diet does not result in boredom and may be
more likely to improve compliance when incorporated into nu-
tritional management for people with T2D. Appetite was shown
to be reduced after breakfast in the group with high-egg intake by
using the visual analog scale, which is a subjective analysis that
has proven to be reproducible, sensitive to exposures of food
components, and predictive of food intake (23, 28). Thus, the
high-egg diet resulted in less hunger and greater satiety after
breakfast than did the low-egg diet, implying that eggs may have
benefits extending beyond their nutritional constituents.
Strengths of this study included the adequate sample size and
low dropout rate of 9%. Despite some small differences in nu-
tritional contents, both groups were well matched for protein
intake. Both groups maintained their starting body weight#1 kg
so that weight loss was not a confounder. The inability to blind
intervention groups when obtaining visual analog scale ratings
of appetite was a limitation as was the short duration of the study.
Furthermore, a significant difference for the primary outcome
may have been shown if the study had a crossover design or used
a larger sample size because the study was powered for a 10%
difference in HDL cholesterol, which was not shown.
TABLE 6
Average scores for each group at baseline and 3 mo for the VAS1
High-egg diet (n = 68) Low-egg diet (n = 66)
Between-group comparison
(high egg relative to low egg)
Before breakfast,
baseline score
After breakfast,
baseline score
Before breakfast,
baseline score
After breakfast,
baseline score
Before breakfast,
D 3 mo
After breakfast,
D 3 mo
Question 1 5.7 6 2.42 1.6 6 2.0 5.2 6 2.6 1.0 6 1.4 0.6 (20.3, 1.5) [0.2]3 20.7 (21.2, 20.1) [0.02]
Question 2 3.5 6 2.4 7.7 6 2.2 3.6 6 2.8 7.4 6 2.4 20.4 (21.2, 0.4) [0.4] 0.2 (20.6, 1.0) [0.6]
Question 3 6.2 6 2.6 1.7 6 2.0 5.6 6 2.8 1.6 6 2.3 0.1 (20.8, 1.0) [0.8] 20.5 (21.1, 0.2) [0.1]
Question 4 6.1 6 2.0 1.7 6 2.0 5.5 6 2.2 1.8 6 2.1 0.0 (20.7, 0.7) [0.9] 20.6 (21.2, 20.0) [0.04]
Question 5 3.5 6 2.6 3.3 6 3.2 3.4 6 2.8 2.8 6 3.2 20.3 (21.1, 0.5) [0.5] 20.2 (21.0, 0.6) [0.6]
Question 6 6.2 6 2.4 1.7 6 2.2 5.3 6 2.9 1.6 6 2.3 0.4 (20.5, 1.4) [0.3] 20.5 (21.2, 0.2) [0.2]
Question 7 5.6 6 2.7 7.3 6 2.5 5.5 6 2.5 7.4 6 2.5 20.1 (21.0, 0.7) [0.8] 0.1 (20.7, 0.9) [0.8]
Question 8 2.6 6 2.3 1.6 6 2.2 2.2 6 2.3 1.1 6 1.6 20.2 (20.9, 0.5) [0.6] 20.5 (21.1, 0.2) [0.2]
Question 9 1.8 6 2.2 1.7 6 2.2 1.5 6 2.1 1.2 6 1.7 0.2 (20.5, 0.9) [0.6] 20.3 (21.0, 0.4) [0.4]
Question 10 7.5 6 2.0 7.9 6 2.0 7.4 6 2.1 7.6 6 2.3 20.6 (21.3, 0.1) [0.1] 20.3 (21.0, 0.3) [0.3]
1The VAS was composed of the following 10 questions scored on a 10-point linear scale with 0 being not at all and 10 being very: Question 1: How
hungry are you? (extreme left of scale = not at all hungry; extreme right of scale = very hungry); Question 2: How full do you feel? (extreme left = not at all
full; extreme right = very full); Question 3: How strong is your desire to eat? (extreme left = not at all strong; extreme right = very strong); Question 4: How
much food do you think you could eat? (extreme left = none at all; extreme right = a large amount); Question 5: How strong is your desire for sweet food?
(extreme left = not at all strong; extreme right = very strong); Question 6: How strong is your desire for savory food? (extreme left = not at all strong; extreme
right = very strong); Question 7. How contented are you? (extreme left = not at all contented; extreme right = very contented); Question 8. How irritable are
you? (extreme left = not at all irritable; extreme right = very irritable); Question 9. How depressed are you? (extreme left = not at all depressed; extreme right =
very depressed); Question 10. How mentally alert are you? (extreme left = not at all alert; extreme right = very alert). Positive D values represent an increase
from baseline; negative D values represent a decrease from baseline. An ANCOVAwas used to compare treatment groups. Analyses were adjusted for baseline
observation. An ANOVAwith repeated measures was used for within-group comparisons. P values represent between-group differences from baseline to 3 mo
after adjustment for the baseline value. VAS, visual analog scale.
2Mean 6 SD (all such values).
3Mean; 95% CI in parentheses; P value in brackets (all such values).
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In conclusion, individuals with prediabetes or T2Dwho consumed
a high-egg diet for 3 mo while maintaining weight and reducing
dietary saturated fat intake (in conjunction with concomitant in-
creases in MUFA and PUFA consumption) had no adverse changes
in circulating lipid profiles compared with in participants who
consumed a low-egg diet. Therefore, a diet including more eggs than
generally recommended may be used safely as part of the nutritional
management of this group.
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